NC318 + pembrolizumab

NC318 + pembrolizumab is a combination immunotherapy regimen under investigation for the treatment of advanced non-small cell lung cancer (NSCLC), particularly in patients who have progressed after prior immune checkpoint inhibitor therapy. - **NC318** is a humanized IgG1 monoclonal antibody that targets Siglec-15 (S15), an immune suppressive protein expressed in the tumor microenvironment. By blocking S15 interactions with myeloid cells and T lymphocytes, NC318 reduces inhibitory signaling and enhances anti-tumor immune responses. - **Pembrolizumab** is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), thereby blocking the PD-1 pathway and preventing cancer cells from evading immune detection. The combination aims to overcome resistance to prior PD-1 axis inhibitors by simultaneously inhibiting two distinct immunosuppressive pathways within tumors. Early phase II clinical trial data show that this regimen can provide durable clinical benefit in pretreated NSCLC patients, including those with PD-L1–negative tumors[5][6][7].

Other names

NC318 plus pembrolizumabNC-318 plus pembrolizumabNC 318 plus pembrolizumabNC318 + Keytruda